C
CirCode Bio develops circular RNA nucleic acid drugs to target genetic diseases by utilizing the unique properties of circular RNA for enhanced stability and efficacy. This approach addresses the limitations of traditional linear RNA therapies, offering a more effective treatment option for conditions that currently lack adequate solutions.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- CirCode Bio develops circular RNA nucleic acid drugs to target genetic diseases by utilizing the unique properties of circular RNA for enhanced stability and efficacy. This approach addresses the limitations of traditional linear RNA therapies, offering a more effective treatment option for conditions that currently lack adequate solutions.